Financing channel feed – Endpoints News

Financing channel feed

Temasek, corporate VCs buy into prescription digital med hopes in Akili's $55M Series C

8 years ago

Evelo Bio grabs $85M as the latest early-stage biotech debuts on Nasdaq

8 years ago

Listing in Shanghai, WuXi AppTec raises a $354M IPO for China R&D facilities

8 years ago

Autolus engineers a $100M-plus IPO for itself as it blueprints a new generation of better, safer cell therapies

8 years ago

Set to be the first pre-revenue biotech to list in Hong Kong, Ascletis lays out priorities in IPO application

8 years ago

Splat: Singapore's Aslan tanks on Nasdaq debut, raising $42M in IPO and trending down

8 years ago

Raising a record $668M in new fund, Foresite sets sights on a tech-driven portfolio

8 years ago

Third Rock sinks $59M into Casma's 'recycling' tech, with neuro on the mind

8 years ago

Iterum tests public market's appetite for anti-infectives in $92M IPO

8 years ago

Chinese investors back Refuge Bio’s $25M B round as it steers gene engineering tech to an IND

8 years ago

Out to ‘rethink the drug design process,’ AI star Daphne Koller is creating a new machine learning venture at insitro with some heavyweight backers

8 years ago

Omega Funds leads $35M Series A to fuel Attenua's cough program, set for proof-of-concept this year

8 years ago

IL-2 without the toxic side effects? Orbimed backs the idea in Synthorx' $63M round

8 years ago

What do you get when you integrate healthcare data from multiple sources into one comprehensive, global package? Travis May says he’s on track to find out

8 years ago

Crescendo snares $70M Series B for its tumor-fighting tech

8 years ago

Alzheon steps back from an IPO, further than ever from a PhIII Alzheimer’s study

8 years ago

IPO plans brewing, Innovent Biologics raises $150M and eyes hundreds of millions more

8 years ago

Amid hot IPO season, Mereo drops Nasdaq plans citing 'challenging' market conditions

8 years ago

Forget Nasdaq. China’s biotechs with blockbuster IPO dreams are switching focus to Hong Kong

8 years ago

Venrock-backed startup Corvidia snags $60M round to develop ex-AstraZeneca drug

8 years ago

After decades in the big leagues, Martin Mackay is going small — and he's delighted

8 years ago

Protein degradation 2.0? Third Rock sinks $56M into Cedilla's unusual approach

8 years ago

Nextech leads a $56M round for the Revolution's move into the clinic

8 years ago

Hong Kong clears way for pre-revenue biotech IPOs, plans to accept listing applications by May

8 years ago

First page Previous page 128 129 130131132 133 134 Next page Last page